Medical Device | December 10, 2021
Indian government approves eight firms for PLI scheme
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Launching in 2022, its availability will be expanded to the global market
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
Subscribe To Our Newsletter & Stay Updated
